Riociguat for the treatment of pulmonary arterial hypertension.

BACKGROUND Riociguat, a soluble guanylate cyclase stimulator, has been shown in a phase 2 trial to be beneficial in the treatment of pulmonary arterial hypertension. METHODS In this phase 3, double-blind study, we randomly assigned 443 patients with symptomatic pulmonary arterial hypertension to receive placebo, riociguat in individually adjusted doses of up to 2.5 mg three times daily (2.5 mg-maximum group), or riociguat in individually adjusted doses that were capped at 1.5 mg three times daily (1.5 mg-maximum group). The 1.5 mg-maximum group was included for exploratory purposes, and the data from that group were analyzed descriptively. Patients who were receiving no other treatment for pulmonary arterial hypertension and patients who were receiving endothelin-receptor antagonists or (nonintravenous) prostanoids were eligible. The primary end point was the change from baseline to the end of week 12 in the distance walked in 6 minutes. Secondary end points included the change in pulmonary vascular resistance, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, World Health Organization (WHO) functional class, time to clinical worsening, score on the Borg dyspnea scale, quality-of-life variables, and safety. RESULTS By week 12, the 6-minute walk distance had increased by a mean of 30 m in the 2.5 mg-maximum group and had decreased by a mean of 6 m in the placebo group (least-squares mean difference, 36 m; 95% confidence interval, 20 to 52; P<0.001). Prespecified subgroup analyses showed that riociguat improved the 6-minute walk distance both in patients who were receiving no other treatment for the disease and in those who were receiving endothelin-receptor antagonists or prostanoids. There were significant improvements in pulmonary vascular resistance (P<0.001), NT-proBNP levels (P<0.001), WHO functional class (P=0.003), time to clinical worsening (P=0.005), and Borg dyspnea score (P=0.002). The most common serious adverse event in the placebo group and the 2.5 mg-maximum group was syncope (4% and 1%, respectively). CONCLUSIONS Riociguat significantly improved exercise capacity and secondary efficacy end points in patients with pulmonary arterial hypertension. (Funded by Bayer HealthCare; PATENT-1 and PATENT-2 ClinicalTrials.gov numbers, NCT00810693 and NCT00863681, respectively.).

[1]  Chen Wang,et al.  Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. , 2013, The New England journal of medicine.

[2]  M. Puhan,et al.  The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. , 2012, American journal of respiratory and critical care medicine.

[3]  R. Benza,et al.  An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. , 2012, Chest.

[4]  H. Palevsky,et al.  Validation of 6-Minute Walk Distance as a Surrogate End Point in Pulmonary Arterial Hypertension Trials , 2012, Circulation.

[5]  W. Seeger,et al.  The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats , 2011, BMC Pharmacology.

[6]  O. V. Evgenov,et al.  Soluble Guanylate Cyclase Stimulation Prevents Fibrotic Tissue Remodeling and Improves Survival in Salt-Sensitive Dahl Rats , 2011, PloS one.

[7]  H. Ghofrani,et al.  Mechanisms of disease: pulmonary arterial hypertension , 2011, Nature Reviews Cardiology.

[8]  Pál Pacher,et al.  Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. , 2011, Circulation.

[9]  J. Stasch,et al.  Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models , 2010, Journal of hypertension.

[10]  F. Grimminger,et al.  Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study , 2010, European Respiratory Journal.

[11]  R. Barst,et al.  Clinical worsening in trials of pulmonary arterial hypertension: results and implications , 2010, Current opinion in pulmonary medicine.

[12]  B. Brundage,et al.  Tadalafil Therapy for Pulmonary Arterial Hypertension , 2009, Circulation.

[13]  N. Weissmann,et al.  First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension , 2009, European Respiratory Journal.

[14]  A. Branzi,et al.  A meta-analysis of randomized controlled trials in pulmonary arterial hypertension , 2008, European heart journal.

[15]  J. Cappelleri,et al.  Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. , 2009, Chest.

[16]  Jeffrey L. Anderson,et al.  ACCF/AHA Expert Conseusus Document , 2009 .

[17]  W. Seeger,et al.  Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension , 2008, European Respiratory Journal.

[18]  B. Wiens,et al.  Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2 , 2008, Circulation.

[19]  W. Seeger,et al.  Activation of Soluble Guanylate Cyclase Reverses Experimental Pulmonary Hypertension and Vascular Remodeling , 2006, Circulation.

[20]  M. Pillinger,et al.  Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension , 2006 .

[21]  Orris,et al.  INHALED ILOPROST FOR SEVERE PULMONARY HYPERTENSION , 2002 .

[22]  Avid,et al.  BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .

[23]  M. Fujita,et al.  Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. , 2000, American journal of respiratory and critical care medicine.

[24]  B. Groves,et al.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.